julien Taieb
julien Taieb
professor of medecine Hopital Europeen Georges Pompidou, Université de Paris (Paris-Descartes
Dirección de correo verificada de egp.aphp.fr
Citado por
Citado por
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial
C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T Andre, ...
Journal of Clinical Oncology 23 (15), 3509-3516, 2005
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
F Ghiringhelli, C Ménard, M Terme, C Flament, J Taieb, N Chaput, ...
The Journal of experimental medicine 202 (8), 1075-1085, 2005
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
T Voron, O Colussi, E Marcheteau, S Pernot, M Nizard, AL Pointet, ...
Journal of Experimental Medicine 212 (2), 139-148, 2015
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
M Suker, BR Beumer, E Sadot, L Marthey, JE Faris, EA Mellon, ...
The Lancet Oncology 17 (6), 801-810, 2016
A novel dendritic cell subset involved in tumor immunosurveillance
J Taieb, N Chaput, C Ménard, L Apetoh, E Ullrich, M Bonmort, ...
Nature medicine 12 (2), 214-219, 2006
Duration of adjuvant chemotherapy for stage III colon cancer
A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ...
New England Journal of Medicine 378 (13), 1177-1188, 2018
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer
M Terme, S Pernot, E Marcheteau, F Sandoval, N Benhamouda, ...
Cancer research 73 (2), 539-549, 2013
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma …
V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ...
The Lancet Oncology 18 (12), 1624-1636, 2017
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα
S Viaud, M Terme, C Flament, J Taieb, F André, S Novault, B Escudier, ...
PloS one 4 (3), e4942, 2009
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects
C Borg, M Terme, J Taïeb, C Ménard, C Flament, C Robert, K Maruyama, ...
The Journal of clinical investigation 114 (3), 379-388, 2004
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection
N Chaput, NEC Schartz, F André, J Taïeb, S Novault, P Bonnaventure, ...
The Journal of Immunology 172 (4), 2137-2146, 2004
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with …
E Tartour, H Pere, B Maillere, M Terme, N Merillon, J Taieb, F Sandoval, ...
Cancer and Metastasis Reviews 30 (1), 83-95, 2011
Identification of CD8+ CD25+ Foxp3+ suppressive T cells in colorectal cancer tissue
N Chaput, S Louafi, A Bardier, F Charlotte, JC Vaillant, F Ménégaux, ...
Gut 58 (4), 520-529, 2009
SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation …
G Van Hazel, V Heinemann, NK Sharma, MPN Findlay, J Ricke, ...
Journal of Clinical Oncology 34 (15), 1723-1731, 2016
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) results of a phase II study
S Louafi, V Boige, M Ducreux, L Bonyhay, T Mansourbakht, T de Baere, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines
J Taieb, N Chaput, N Schartz, S Roux, S Novault, C Ménard, ...
The Journal of Immunology 176 (5), 2722-2729, 2006
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
J Taieb, J Tabernero, E Mini, F Subtil, G Folprecht, JL Van Laethem, ...
The lancet oncology 15 (8), 862-873, 2014
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction …
YJ Bang, EY Ruiz, E Van Cutsem, KW Lee, L Wyrwicz, M Schenker, ...
Annals of Oncology 29 (10), 2052-2060, 2018
Control of the immune response by pro-angiogenic factors
T Voron, E Marcheteau, S Pernot, O Colussi, E Tartour, J Taieb, M Terme
Frontiers in oncology 4, 70, 2014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20